{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:08:11Z","timestamp":1789546091329,"version":"build-2803163510"},"reference-count":28,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prader\u2013Willi syndrome (PWS) is a neurogenetic disorder characterized by hyperphagia, severe obesity, and early-onset metabolic complications, in which durable weight loss is rarely achieved. We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185\u2005kg; body mass index [BMI] 59.7\u2005kg\/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67\u2005mmol\/mol] [reference range, &amp;lt;5.7% (SI: &amp;lt;39\u2005mmol\/mol)]). He received sequential incretin-based therapy, initiated with retatrutide (1-12\u2005mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise. At 18 months, total weight loss reached 58.8% (\u2212108.7\u2005kg), with HbA1c of 4.9% (SI: 30\u2005mmol\/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications. Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events. Follow-up bioimpedance showed a skeletal muscle mass of 38.5\u2005kg after a 58.8% reduction in total body weight.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag260","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:23:09Z","timestamp":1787570589000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained weight loss exceeding 100\u2005kg with sequential incretin-based therapy in Prader\u2013Willi syndrome"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-7736","authenticated-orcid":false,"given":"Marlon","family":"Yovera-Aldana","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n de Neurociencias, Metabolismo, Efectividad Cl\u00ednica y Sanitaria, Universidad Cient\u00edfica del Sur , Lima 15816 ,","place":["Per\u00fa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-6147","authenticated-orcid":false,"given":"Helard","family":"Manrique-Hurtado","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Delgado\u2014AUNA Deparment of Endocrinology, , Lima 15074 ,","place":["Per\u00fa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine Division of Endocrinology, Department of Medicine, , Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"4","key":"2026091603525316500_luag260-B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1573396315666190716120925","article-title":"Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update","volume":"15","author":"Butler","year":"2019","journal-title":"Curr Pediatr Rev"},{"issue":"4","key":"2026091603525316500_luag260-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13679-022-00478-w","article-title":"Prader\u2013Willi syndrome in adults: an update on nutritional treatment and pharmacological approach","volume":"11","author":"Barrea","year":"2022","journal-title":"Curr Obes Rep"},{"issue":"1","key":"2026091603525316500_luag260-B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12020-022-03064-1","article-title":"Intensive management of obesity in people with Prader-Willi syndrome","volume":"77","author":"Nolan","year":"2022","journal-title":"Endocrine"},{"issue":"2","key":"2026091603525316500_luag260-B4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.6065\/apem.2142022.011","article-title":"Tailored management of life-threatening complications related to severe obesity in a young adult with Prader-Willi syndrome","volume":"27","author":"Kim","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"2","key":"2026091603525316500_luag260-B5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/cen.14583","article-title":"The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader\u2013Willi syndrome: a systematic review","volume":"96","author":"Ng","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026091603525316500_luag260-B6","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.5195\/ijms.2025.3992","article-title":"Managing hyperphagia, obesity, and hyperglycemia in Prader-Willi syndrome: a meta-analysis of GLP-1 agonists and SGLT2 inhibitors","volume":"13","author":"Mulluri","year":"2025","journal-title":"Int J Med Stud"},{"issue":"7","key":"2026091603525316500_luag260-B7","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","article-title":"Diazoxide choline extended-release tablet in people with Prader\u2013Willi syndrome: a double-blind, placebo-controlled trial","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026091603525316500_luag260-B8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2024.1940","article-title":"Glucagon-like peptide-1 based therapies: a new horizon in obesity management","volume":"39","author":"Son","year":"2024","journal-title":"Endocrinol Metab"},{"issue":"5","key":"2026091603525316500_luag260-B9","first-page":"555949","article-title":"Retatrutide as a novel treatment for obesity and type 2 Diabetes","volume":"16","author":"Mikhail","year":"2023","journal-title":"Curr Res Diabetes Obes J"},{"issue":"6","key":"2026091603525316500_luag260-B10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2026091603525316500_luag260-B11","doi-asserted-by":"crossref","first-page":"e12992","DOI":"10.1111\/obr.12992","article-title":"Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: a narrative review","volume":"21","author":"Tan","year":"2019","journal-title":"Obes Rev"},{"issue":"10","key":"2026091603525316500_luag260-B12","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40618-021-01574-9","article-title":"Obesity in Prader\u2013Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches","volume":"44","author":"Muscogiuri","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026091603525316500_luag260-B13","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms24032150","article-title":"Clinical trials in Prader\u2013Willi syndrome: a review","volume":"24","author":"Mahmoud","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026091603525316500_luag260-B14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for weight management in children and adolescents with Prader\u2013Willi syndrome and obesity","volume":"108","author":"Diene","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091603525316500_luag260-B15","doi-asserted-by":"crossref","first-page":"1528457","DOI":"10.3389\/fendo.2024.1528457","article-title":"Case report: long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review","volume":"15","author":"Koceva","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026091603525316500_luag260-B16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/oby.23928","article-title":"Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study","volume":"32","author":"Miller","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"2026091603525316500_luag260-B17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.soard.2023.01.017","article-title":"Metabolic and bariatric surgery for obesity in Prader Willi syndrome: systematic review and meta-analysis","volume":"19","author":"Wolfe","year":"2023","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"2026091603525316500_luag260-B18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1542\/peds.113.3.565","article-title":"Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy","volume":"113","author":"Butler","year":"2004","journal-title":"Pediatrics"},{"issue":"8","key":"2026091603525316500_luag260-B19","doi-asserted-by":"crossref","first-page":"e72640","DOI":"10.1371\/journal.pone.0072640","article-title":"Psychiatric illness and intellectual disability in the Prader\u2013Willi syndrome with different molecular defects - a meta analysis","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2026091603525316500_luag260-B20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1352\/0895-8017(1999)104<0067:MBDIPS>2.0.CO;2","article-title":"Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus paternal uniparental disomy","volume":"104","author":"Dykens","year":"1999","journal-title":"Am J Ment Retard"},{"issue":"1","key":"2026091603525316500_luag260-B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s11689-017-9200-2","article-title":"Diagnoses and characteristics of autism spectrum disorders in children with Prader-Willi syndrome","volume":"9","author":"Dykens","year":"2017","journal-title":"J Neurodev Disord"},{"issue":"12","key":"2026091603525316500_luag260-B22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings","volume":"38","author":"Angulo","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026091603525316500_luag260-B23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3390\/ijms22041993","article-title":"Hypogonadism in patients with Prader Willi syndrome: a narrative review","volume":"22","author":"Napolitano","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026091603525316500_luag260-B24","first-page":"83","article-title":"Male obesity-related secondary hypogonadism\u2014pathophysiology, clinical implications and management","volume":"15","author":"Fernandez","year":"2019","journal-title":"Eur Endocrinol"},{"key":"2026091603525316500_luag260-B25","doi-asserted-by":"crossref","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"8","key":"2026091603525316500_luag260-B26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026091603525316500_luag260-B27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000499607","article-title":"Limitations of fat-free mass for the assessment of muscle mass in obesity","volume":"12","author":"Jensen","year":"2019","journal-title":"Obes Facts"},{"issue":"2","key":"2026091603525316500_luag260-B28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2265.1995.tb01860.x","article-title":"Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults","volume":"42","author":"Beshyah","year":"1995","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/10\/luag260\/71115201\/luag260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/10\/luag260\/71115201\/luag260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:53:00Z","timestamp":1789545180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag260\/8800978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag260","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,3]]},"article-number":"luag260"}}